Methadone Information
"Methadone was developed by German scientists in the late 1930s.
It was approved by the U.S. Food and Drug Administration (FDA)
in 1947 as a painkiller, and by 1950 oral methadone also was
used to treat the painful symptoms of persons withdrawing from
opioids, usually heroin."
"In 1964, researchers at Rockefeller University, New York...
believed that opioid addiction was a "metabolic disease" that
altered brain function and made it difficult for patients to
remain drug-free. [They]...discovered that an ongoing, daily dose
of long-acting oral methadone -- maintenance treatment -- offered
a number of beneficial effects allowing otherwise debilitated opioid
addicts to function more normally."
"Oral methadone has demonstrated a favorable safety profile when
properly prescribed and used. No serious adverse reactions or organ
damage have been specifically associated with continued methadone
use extending more than 20 years in some patients...Women stabilized
on methadone generally have more healthful pregnancies and their
newborns do not suffer any lasting adverse consequences. Furthermore,
methadone at appropriate dose levels does not hinder a patient's
intellectual capacities or abilities to perform work tasks."
MMT Benefits:
- An adequate maintenance dose of methadone does not make the patient
feel "high" or drowsy, so the patient can generally carry on a normal
life. Daily drug-seeking to "feed a habit" ceases.
- Methadone can be taken once daily by mouth without the use of
injection needles, which limits exposure to diseases like hepatitis
and HIV.
- Methadone's gradual, long-lasting effects eliminate drug hunger
or craving.
- There is little change in tolerance to methadone over time, so it
does not take more of the drug to achieve the same results.
- Euphoria-blocking effects of methadone make taking illicit opioids
undesirable.
- Used properly, methadone is generally safe and nontoxic, with
minimal side effects.
[Source: Addiction Treatment Forum, Methadone Maintenance Treatment (MMT),
Stewart B. Leavitt, PhD, Editor]